Apollo Life Sciences was listed on the Australian Stock Exchange in June 2005 and is traded under the symbol AOP. Apollo is committed to regular and relevant communication with shareholders and the market in general.

Apollo Life Sciences is an innovative biotechnology company that has made major breakthroughs in the areas of drug delivery and expression of proteins from human cells. Apollo’s combined technologies are expected to lead to more effective and lower cost therapeutics, compared to first generation protein-based drugs.

The most advanced products in Apollo’s therapeutic development pipeline are in the areas of diabetes, with oral insulin, and inflammation, with topical psoriasis and oral and topical rheumatoid arthritis treatments.

Apollo is currently selling research proteins and detection kits in the life sciences consumables market and is entering the skin renewal and inflammation segments of the over-the-counter market.